Most drugs tested against age-related diseases are never evaluated for whether they also slow biological aging itself — a missed opportunity that could redefine how we interpret clinical trial data. A new approach published in Nature Biotechnology proposes embedding proteomic aging clocks directly into existing disease-focused trials, potentially doubling the scientific yield of each study without adding a single extra participant.
The analysis applied six established proteomic aging clocks — ProtAge, OrganAge (mortality and chronological variants), PAC, ipfP3GPT, and PAOPAC — to serum proteome data collected during a 12-week phase 2a trial of rentosertib, a candidate anti-fibrotic agent tested in idiopathic pulmonary fibrosis (IPF). Critically, all six clocks independently agreed: patients in the treated arms showed lower predicted biological age compared to controls. This cross-clock consistency is notable, since epigenetic clocks — the previous gold standard — routinely produce contradictory or opaque results across cohorts. Pathway analyses further identified shifts in senescence-associated signaling and metabolic regulation that are mechanistically distinct from rentosertib's known anti-fibrotic mechanism, hinting at broader geroprotective activity.
The implications extend well beyond any single drug or disease. Regulatory agencies have not yet accepted biological age as a clinical endpoint, and a persistent methodological weakness has been that proteomic clock outputs conflate true aging deceleration with disease-specific protein shifts — a confound this work openly acknowledges but only partially resolves through pathway decomposition. Still, this is arguably a paradigm-shifting methodological contribution: it demonstrates that proteomic aging clocks are sufficiently reproducible and sensitive to serve as secondary endpoints in short-duration human trials. For the longevity-medicine field, which has struggled to conduct aging-specific trials due to timeline and regulatory constraints, embedding geroprotective endpoints into disease trials offers a practical near-term path. The 12-week window is short, the cohort is disease-specific, and replication in metabolically healthy populations will be essential — but the proof-of-concept is compelling and broadly actionable.
